Abstract: The invention provides novel BTNL3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to BTNL3 proteins and nucleic acids encoding BTNL3 proteins are provided. Methods of making BTNL3 proteins using such nucleic acids are also provided. Uses for BTNL3 proteins, and agonists or antagonists thereof, are described.
Type:
Grant
Filed:
January 24, 2019
Date of Patent:
October 4, 2022
Assignee:
Amgen Inc.
Inventors:
Heather Arnett, Sabine Schadow Escobar, Ryan Michael Swanson, Joanne Louise Viney
Abstract: A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula.
Type:
Grant
Filed:
November 9, 2016
Date of Patent:
October 4, 2022
Assignee:
AMGEN INC.
Inventors:
Lawrence S. Ring, Dhairya Mehta, Stephanie Toy, Ferry Tamtoro, Alexander Stuart Cairns, Scott R. Gibson
Abstract: Described herein are therapeutic protein formulations comprising N-methyl pyrrolidone (NMP), methods related to reducing viscosity of pharmaceutical formulations and methods related to stabilizing pharmaceutical formulations using NMP.
Type:
Grant
Filed:
October 6, 2017
Date of Patent:
October 4, 2022
Assignee:
Amgen Inc.
Inventors:
Alona Teran, Qahera Munaim, Nazer Khalaf, Rahul Rajan Kaushik, Christi L. Clogston, Twinkle R. Christian, William J. Callahan
Abstract: The present invention relates to RNAi constructs for reducing expression of the SCAP gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
Type:
Application
Filed:
June 1, 2020
Publication date:
September 29, 2022
Applicant:
AMGEN INC.
Inventors:
Amrita DAS, Bradley J. HERBERICH, Justin K. MURRAY, Oliver HOMANN, Michael OLLMANN, Daniel C.H. LIN
Abstract: The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I), an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.
Type:
Application
Filed:
June 10, 2021
Publication date:
September 29, 2022
Applicant:
AMGEN INC.
Inventors:
Benjamin C MILGRAM, Isaac E MARX, Haoxuan WANG, Alan H CHERNEY
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc fusion molecules that preferentially expand and activate cells and are amenable to large scale production. Also provided herein are methods of making and using the compositions of the present invention.
Type:
Application
Filed:
August 13, 2020
Publication date:
September 15, 2022
Applicant:
AMGEN INC.
Inventors:
Darren L. BATES, Sue J. SOHN, Hannah Beth CATTERALL, Zhulun WANG
Abstract: Amide compounds of formula (I): and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of Kinesin Motor Protein KIF18A, such as cancer, psoriasis, atopic dermatitis, an autoimmune disorder, or inflammatory bowel disease, and the like.
Type:
Application
Filed:
August 3, 2020
Publication date:
September 15, 2022
Applicant:
AMGEN INC.
Inventors:
Nuria A. TAMAYO, Abhisek BANERJEE, Jian Jeffrey CHEN, Matthew Paul BOURBEAU, Matthew Richard KALLER, Jonathan Dante LOW, Ana Elena MINATTI, Thomas T. NGUYEN, Nobuko NISHIMURA, Liping H. PETTUS, Mary Catherine WALTON, Qiufen May XUE, John Gordon ALLEN
Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
Type:
Grant
Filed:
November 18, 2019
Date of Patent:
September 13, 2022
Assignee:
Amgen Inc.
Inventors:
James Russell Lipford, Jude Robert Canon, Anne Y. Saiki, Karen Louise Rex
Abstract: A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula.
Type:
Grant
Filed:
January 31, 2020
Date of Patent:
September 13, 2022
Assignee:
AMGEN INC.
Inventors:
Lawrence Ring, Dhairya Mehta, Stephanie Toy, Ferry Tamtoro, Alexander Stuart Cairns, Scott R. Gibson
Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
Type:
Application
Filed:
August 3, 2020
Publication date:
September 8, 2022
Applicant:
AMGEN INC.
Inventors:
Nuria A. TAMAYO, Abhisek BANERJEE, Matthew Paul BOURBEAU
Abstract: The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided.
Type:
Application
Filed:
July 24, 2020
Publication date:
September 8, 2022
Applicant:
AMGEN INC.
Inventors:
Agnieszka KIELCZEWSKA, Ian Nevin FOLTZ, Palaniswami RATHANASWAMI, Maria Sheena AMADOR, Bram ESTES, Igor D'ANGELO
Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
Type:
Application
Filed:
October 13, 2021
Publication date:
September 8, 2022
Applicant:
AMGEN INC.
Inventors:
Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
Abstract: Magnetic assisted separation apparatuses for separating a target substance from a medium in which the target substance is suspended, and related methods, are provided. According to one aspect, a magnetic separator may include a frame having an opening configured to receive one or more containers containing the medium. Additionally, the magnetic separator may include first and second magnetic field generating elements mounted on opposing sides of the frame such that one or more containers can be positioned between the first and second magnetic field generating elements. According to another aspect, a workstation includes a work surface for receiving one or more containers containing the medium, a fluid transfer member, an automated manipulator configured to move the fluid transfer member, and a plurality magnetic field generating elements each being moveable between a position remote from the one or more containers and another position adjacent to the one or more containers.
Type:
Grant
Filed:
June 26, 2018
Date of Patent:
September 6, 2022
Assignee:
AMGEN INC.
Inventors:
Craig Michael Schulz, Justin James Provchy, John Kasajja Kawooya
Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.
Type:
Grant
Filed:
June 16, 2014
Date of Patent:
September 6, 2022
Assignee:
AMGEN INC.
Inventors:
Christopher James Sloey, Jason Ko, Tiansheng Li
Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
Abstract: A purification system and method may include a container receiving portion, pump, and magnetic field generating element. The container receiving portion may be configured to receive and support a container containing a mixture. Magnetic beads may be added to the container for separating a target substance from a remainder of the mixture. The magnetic field generating element may be movable relative to the container receiving portion between a non-working position remote from the container receiving portion and a working position adjacent an outer periphery of the container receiving portion. In the working position, the magnetic field generating element may attract the magnetic beads and hold them firmly against an interior surface of the container. While the magnetic beads are immobilized by the magnetic field generating element, the pump may remove the mixture from the container, leaving behind the magnetic beads bound tightly but reversibly to the target substance.
Type:
Grant
Filed:
November 6, 2020
Date of Patent:
September 6, 2022
Assignee:
AMGEN INC.
Inventors:
Craig Michael Schulz, Justin James Provchy, John Kasajja Kawooya